Raras
Buscar doenças, sintomas, genes...
Insulinoma
ORPHA:97279CID-10 · D37.7CID-11 · 2C10.1DOENÇA RARA

Tumor neuroendócrino produtor de insulina que surge das células beta do pâncreas. Pode ou não estar associada à secreção inadequada de insulina e a uma síndrome clínica associada.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Tumor neuroendócrino produtor de insulina que surge das células beta do pâncreas. Pode ou não estar associada à secreção inadequada de insulina e a uma síndrome clínica associada.

Pesquisas ativas
7 ensaios
64 total registrados no ClinicalTrials.gov
Publicações científicas
6.860 artigos
Último publicado: 2026 Mar

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.56
Japan
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D37.7
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
8 sintomas
🧠
Neurológico
6 sintomas
🫘
Rins
2 sintomas
👁️
Olhos
1 sintomas
👂
Ouvidos
1 sintomas
🦴
Ossos e articulações
1 sintomas

+ 13 sintomas em outras categorias

Características mais comuns

90%prev.
Hipoglicemia recorrente
Muito frequente (99-80%)
90%prev.
Hipoglicemia hiperinsulinêmica
Muito frequente (99-80%)
90%prev.
Palpitações
Muito frequente (99-80%)
90%prev.
Tremor
Muito frequente (99-80%)
90%prev.
Morfologia anormal das células das ilhotas pancreáticas
Muito frequente (99-80%)
90%prev.
Amnésia global transitória
Muito frequente (99-80%)
34sintomas
Muito frequente (11)
Frequente (10)
Ocasional (13)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 34 características clínicas mais associadas, ordenadas por frequência.

Hipoglicemia recorrenteRecurrent hypoglycemia
Muito frequente (99-80%)90%
Hipoglicemia hiperinsulinêmicaHyperinsulinemic hypoglycemia
Muito frequente (99-80%)90%
PalpitaçõesPalpitations
Muito frequente (99-80%)90%
Tremor
Muito frequente (99-80%)90%
Morfologia anormal das células das ilhotas pancreáticasAbnormality of the pancreatic islet cells
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico6.860PubMed
Últimos 10 anos200publicações
Pico2025142 papers
Linha do tempo
2026Hoje · 2026🧪 1991Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

YY1Transcriptional repressor protein YY1Disease-causing somatic mutation(s) inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that exhibits positive and negative control on a large number of cellular and viral genes by binding to sites overlapping the transcription start site (PubMed:15329343, PubMed:17721549, PubMed:24326773, PubMed:25787250). Binds to the consensus sequence 5'-CCGCCATNTT-3'; some genes have been shown to contain a longer binding motif allowing enhanced binding; the initial CG dinucleotide can be methylated greatly reducing the binding affinity (PubMed:15329343, Pu

LOCALIZAÇÃO

Nucleus matrix

VIAS BIOLÓGICAS (5)
Estrogen-dependent gene expressionDNA Damage Recognition in GG-NERUCH proteinasesTFAP2 (AP-2) family regulates transcription of growth factors and their receptorsActivation of anterior HOX genes in hindbrain development during early embryogenesis
MECANISMO DE DOENÇA

Gabriele-de Vries syndrome

An autosomal dominant neurodevelopmental disorder characterized by delayed psychomotor development and intellectual disability. Most patients have behavioral and feeding problems, movement abnormalities, mild distal skeletal anomalies, and dysmorphic facial features.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
55.4 TPM
Artéria tibial
44.1 TPM
Cérebro - Hemisfério cerebelar
44.1 TPM
Útero
39.6 TPM
Nervo tibial
38.5 TPM
OUTRAS DOENÇAS (2)
Gabriele de Vries syndromepancreatic insulin-producing neuroendocrine tumor
HGNC:12856UniProt:P25490
MEN1MeninMajor susceptibility factor inAltamente restrito
FUNÇÃO

Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionDeactivation of the beta-catenin transactivating complexFormation of the beta-catenin:TCF transactivating complexFormation of WDR5-containing histone-modifying complexes
MECANISMO DE DOENÇA

Familial multiple endocrine neoplasia type I

Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
45.1 TPM
Tireoide
43.2 TPM
Cérebro - Hemisfério cerebelar
40.2 TPM
Fibroblastos
37.9 TPM
Baço
35.0 TPM
OUTRAS DOENÇAS (7)
multiple endocrine neoplasia type 1pituitary gigantismnull pituitary adenomaprolactin-producing pituitary gland adenoma
HGNC:7010UniProt:O00255

Variantes genéticas (ClinVar)

973 variantes patogênicas registradas no ClinVar.

🧬 MEN1: NM_001370259.2(MEN1):c.1186-1G>C ()
🧬 MEN1: NM_001370259.2(MEN1):c.767T>G (p.Leu256Arg) ()
🧬 MEN1: NM_001370259.2(MEN1):c.1009G>A (p.Ala337Thr) ()
🧬 MEN1: NM_001370259.2(MEN1):c.478dup (p.Ala160fs) ()
🧬 MEN1: NM_001370259.2(MEN1):c.361dup (p.Val121fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 25
1Fase 15
·Pré-clínico10
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Insulinoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

4 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

64 ensaios clínicos encontrados, 7 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.252 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.252

#1

Development and characterization of experimental β-cell senescence models revealing autophagy defects and altered stimulus-secretion coupling.

GeroScience2026 Mar 09

Aging is a major contributor to β-cell dysfunction in type 2 diabetes, with cellular senescence increasingly recognized as an important underlying mechanism. Here, we established a doxorubicin (DOX)-induced senescence model using MIN6 mouse insulinoma β-cell line to elucidate the mechanisms by which senescence remodels organelle homeostasis and insulin secretion. Senescence was validated by senescence-associated β-galactosidase positivity, p16INK4a/p21/p53 upregulation, and cell cycle arrest. Using mitochondrial MitoTimer and cytochrome c oxidase subunit 8-enhanced green fluorescent protein-mCherry reporters, along with a custom Insulin-Timer construct, we visualized organelle aging and assessed β-cell functions via glucose-stimulated insulin secretion, insulin content, mitochondrial membrane potential, Ca2⁺ imaging, and reactive oxygen species production analyses. Senescent β-cells accumulated mitochondria and insulin granules with prolonged residence time since synthesis and exhibited defective clearance and exaggerated mitochondrial hyperpolarization accompanied by altered Ca2⁺ influx and enhanced reactive oxygen species production upon glucose stimulation. Despite the reduced insulin content, secretion normalized to storage was disproportionately enhanced, suggesting remodeled stimulus-secretion coupling; similar findings were also observed in the p16INK4a/p21/p53 overexpression model. This study provides evidence that DOX-induced β-cell senescence serves as a surrogate model linking DNA damage to impaired mitochondrial and insulin granule clearance. By mimicking aspects of age-related β-cell dysfunction, this model highlighted autophagy defects as drivers of organelle retention and provided insights into the mechanisms by which senescence reshapes stimulus-secretion coupling, thereby enhancing our understanding of β-cell senescence in diabetes. Importantly, this experimentally tractable model provides a platform to test interventions targeting senescent-cell burden or senescence-associated dysfunction and to dissect mechanisms of β-cell functional remodeling.

#2

Evaluation of Clinical, Laboratory and Immunological Characteristics in the Early Onset (Diagnosed Age < 30 Years Old) Patients With Type 2 Diabetes.

Journal of Korean medical science2026 Feb 23

The classification of early onset (< 30 years old) patients with diabetes mellitus (DM) as either type 1 diabetes (T1D) or type 2 diabetes (T2D) can be a challenge due to their similar overlapping phenotypes. In this study, we attempted to utilize various clinical and laboratory characteristics in combination with immunological factors in the blood to determine whether it would be possible to distinguish and more accurately characterize our patients as T2D. Electronic medical records were evaluated to obtain information categorized as either early onset patients with DM (n = 102) and patients with T1D (n = 89). Using the stored serum from these patients, autoantibodies of anti-insulinoma associated 2 (IA2), anti-zinc transporter 8 (ZnT8) and anti-glutamic acid decarboxylase antibody (GAD) were measured. In the clinical characteristics, early onset patients with DM (n = 102) were younger (31.7 ± 7.0 years old, P < 0.01), more overweight (28.1 ± 5.5 kg/m², P < 0.05), shorter duration of diabetes (10.4 ± 7.3 years, P < 0.01) and a more prevalent family history of diabetes (81%, P < 0.01) than patients with T1D. The laboratory values from early onset patients with DM exhibited lower glycated hemoglobin A1c (8.0 ± 2.1%, P < 0.01) and glucose levels (165 ± 73 mg/dL, P < 0.01) with conversely higher C-peptide levels (2.2 ± 1.2 ng/mL, P < 0.01). Measurements of immunological factors, demonstrated that the prevalence of anti-ZnT8 (2%) and anti-GAD antibody (2%) in early onset patients with DM was significantly lower (P < 0.01) compared to patients with T1D (13% for anti-ZnT8 and 38% for anti-GAD). The prevalence of anti-IA2 was not significantly different between early onset patients with DM (13%) versus patients with T1D (11%). In the multivariate logistic regression analysis, C-peptide level (B, 4.453; standard error [SE], 0.844; Wald, 27.808; P < 0.001) was the strongest independent factor to distinguish early onset patients with DM as T2D. After adjusting C-peptide level, family history of diabetes (B, 0.830; SE, 0.420; Wald, 3.909; P = 0.048), body mass index (BMI) (B, 0.111; SE, 0.039; Wald, 8.167; P = 0.004) and the relative negative status of anti-GAD (B, -2.041; SE, 0.597; Wald, 11.670; P < 0.001) were determining factors in our analyses. In this study, our findings suggested that early onset patients with DM may be more accurately diagnosed as T2D if they have a compilation of elevated C-peptide levels, higher BMI, more prevalent history of familial diabetes and the absence of detecting anti-GAD antibodies.

#3

Targeted near-infrared imaging utilizing a cathepsin-activated fluorophore for the intraoperative detection of canine insulinoma.

PloS one2026

The aim of this study was to evaluate the use of cathepsin-activated intraoperative near-infrared (NIR) imaging to detect insulinomas in dogs, a spontaneous large animal model for human disease. A prospective, pilot clinical trial was performed on dogs with naturally occurring insulinomas undergoing exploratory laparotomy. Each dog underwent routine preoperative diagnostic assessment, and a cathepsin-activated fluorophore (VGT-309) was administered intravenously 1-2 days preoperatively. All intraoperative findings with visible light and NIR imaging were recorded and mean NIR fluorescence intensity of tumors and grossly normal pancreas were quantified. Excision of any identified primary tumor and suspected metastatic lesions was performed. All excised tissues underwent histologic evaluation and immunohistochemistry (IHC) for cathepsin B expression. Descriptive statistics were calculated, and differential fluorescence intensity and cathepsin B expression between the pancreatic mass and adjacent grossly normal pancreatic tissue were assessed for statistical significance via paired t tests with p < 0.05 used for significance. Six dogs were enrolled. No adverse events occurred secondary to administration of the imaging agent. In situ, insulinomas had significantly greater mean fluorescence intensities than the surrounding pancreas, and the median tumor to background ratio was 1.906 (range 1.286-2.556). One dog had an occult pancreatic mass that was identified intraoperatively with NIR guidance. Background fluorescence of liver and lymph nodes was observed in all cases, and one dog was diagnosed with nodal and hepatic metastasis. Histologic tumor margins correlated with margins of NIR fluorescence. Cathepsin B expression was determined to be significantly greater in the pancreatic tumor compared to adjacent non-neoplastic pancreas via IHC, and there was no overlap in the range of median IHC-positive proportion values for these tissues. However, there was overlap in the range of IHC-positive proportion values for neoplastic pancreatic samples and lymph node and liver tissues. The findings of this pilot study support further investigation of cathepsin-activated NIR imaging to enhance intraoperative canine insulinoma localization and margin evaluation. Future studies are needed to further characterize and optimize the utility of targeted NIR imaging, particularly to identify metastatic lesions, for canine insulinoma, which may serve as an effective translational model for humans with pancreatic neuroendocrine tumors.

#4

Type 1 Diabetes: A Review.

JAMA2026 Mar 24

Type 1 diabetes is defined by hyperglycemia due to autoimmune destruction of the insulin-producing beta cells in the pancreas, leading to insulin deficiency, and accounts for 5% to 10% of all cases of diabetes. Type 1 diabetes affects approximately 2 million people in the US and 8.4 million people worldwide and is associated with microvascular and macrovascular complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease. Ninety percent to 95% of people with type 1 diabetes have at least 1 autoantibody when they are diagnosed with diabetes. These autoantibodies include autoantibodies to insulin, glutamic acid decarboxylase 65, insulinoma-associated 2, and zinc transporter 8 autoantibodies and are absent in type 2 diabetes or monogenic diabetes (a rarer form of diabetes caused by a single genetic variant). These autoantibodies are present before clinical symptoms develop and can identify early stages of type 1 diabetes. Up to 44% of children and 23% of adults with type 1 diabetes present with diabetes-related ketoacidosis. Type 1 diabetes is most commonly diagnosed between ages 10 and 14 years, but the median age of diagnosis in the US is 24 years. People with type 1 diabetes require lifelong insulin replacement, which can be administered via subcutaneous injection or insulin pump. Insulin regimens that mimic normal physiology include long-acting basal insulin (eg, glargine or degludec) administered once to twice daily and rapid-acting bolus insulin (eg, aspart or lispro) administered prior to meals that contain carbohydrates and during periods of hyperglycemia. Randomized clinical trials have demonstrated that continuous glucose monitors with insulin pumps, which automatically adjust insulin delivery in response to glucose levels, result in less hypoglycemia and improved hemoglobin A1c levels (with the greatest improvement occurring in those with higher starting levels [eg, >8.0%]). Type 1 diabetes accounts for 5% to 10% of all cases of diabetes and is characterized by the presence of islet autoantibodies in 90% to 95% of patients. Lifelong use of insulin therapy is currently required for treatment of type 1 diabetes.

#5

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma.

BMJ case reports2026 Jan 27

A man in his mid-30s presented to the emergency department following a motor vehicle accident with critically low blood glucose of 1.1 mmol/L (3.9-5.6 mmol/L) noted by emergency medical service and altered mental status. The patient reported progressive symptoms including tremor, sweating and difficulty concentrating, requiring continuous eating throughout the day, weight gain and hypoglycaemia unawareness.A 72-hour supervised fast confirmed endogenous hyperinsulinaemia, after 5 hours, inappropriately elevated insulin of 26 pmol/L (diagnostic cut-off ≥18 pmol/L) and C-peptide >0.33 nmol/L (expected <0.2 nmol/L) with glucose 2.2 mmol/L (3.9-5.6 mmol/L). While CT and DOTATATE-positron emission tomography were negative, endoscopic ultrasound (EUS) and biopsy identified a 13 mm pancreatic head well-differentiated neuroendocrine tumour.EUS-guided radiofrequency ablation (EUS-guided RFA) achieved immediate symptom resolution with normal postprocedure biochemical profile. In this case, EUS successfully identified the lesion when conventional imaging was negative and EUS-guided RFA resulted in successful treatment in this patient.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.971 artigos no totalmostrando 196

2026

Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models.

Frontiers in oncology
2026

Vestibular Dysfunction as a Novel Presentation of Middle Ear Neuroendocrine Tumor.

Journal of neurological surgery reports
2026

[18F]FB(ePEG12)12-Exendin-4 positron emission tomography/magnetic resonance imaging for precise preoperative localization of a pancreatic-head insulinoma: a case report with review of literature.

Endocrine journal
2026

Clinical signs, management, and survival of 278 dogs diagnosed with insulinoma under primary veterinary care in the United Kingdom.

Journal of veterinary internal medicine
2026

Clinical Characteristics and Risk Factors of Exogenous Insulin Antibody Syndrome in Patients with Diabetes: A Retrospective Cross-Sectional Study.

Diabetes, metabolic syndrome and obesity : targets and therapy
2026

Insulinoma complicated with hypergastrinemia in a subject with type 2 diabetes mellitus: a case report.

Diabetology international
2026

Development and characterization of experimental β-cell senescence models revealing autophagy defects and altered stimulus-secretion coupling.

GeroScience
2026

Contrast-enhanced endoscopic ultrasound-guided additional ethanol ablation after early detection of occult residual pancreatic insulinoma.

Endoscopy
2026

A Rare Case of Asymptomatic Insulinoma with Mesocolonic Lymph Node Metastases and Long-Term Stability.

Surgical case reports
2026

Explainable deep learning and radiomics integration for differentiating insulinomas from NF-PNETs in EUS imaging.

BMC medical informatics and decision making
2026

A rare case of ectopic cushing's syndrome caused by renal neuroendocrine tumor.

Journal of diabetes and metabolic disorders
2026

A Case of Antibody-Mediated Recurrent Hypoglycemia in a Patient With Mixed Connective Tissue Disease.

Cureus
2026

Transcriptomic profiling of insulinomas reveals a new "low-endocrine" subtype with low YY1 expressions.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
2026

Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model.

Endocrine-related cancer
2026

Evaluation of Clinical, Laboratory and Immunological Characteristics in the Early Onset (Diagnosed Age < 30 Years Old) Patients With Type 2 Diabetes.

Journal of Korean medical science
2026

Targeted near-infrared imaging utilizing a cathepsin-activated fluorophore for the intraoperative detection of canine insulinoma.

PloS one
2026

Paralytic Ileus as the Initial Manifestation of New-Onset Type 1 Diabetes Without Diabetic Ketoacidosis: A Case Report.

Cureus
2026

Arachidonic Acid and Lipoxin A4 Protect Pancreatic β-Cells and Improve Hyperglycemia Induced by Bleomycin.

Journal of biochemical and molecular toxicology
2026

Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.

Endocrine journal
2026

Insulin Autoimmune Syndrome Associated With Hashimoto Thyroiditis and Nodular Thyroid Disease: Clinical Management With Flash Glucose Monitoring and Prednisolone Therapy.

The American journal of case reports
2026

Type 1 Diabetes: A Review.

JAMA
2026

Insulinoma with postprandial hypoglycemia and characteristic expression of GLUT2/GCK/GLP-1R.

The Journal of endocrinology
2026

Thymic Atypical Carcinoid Mimicking Recurrent Type A Thymoma on Frozen Section: A Diagnostic Pitfall Resolved by Intraoperative Imprint Cytology.

Cureus
2026

When Morphology Misleads: The Diagnostic Challenge of Large-Cell Variant Merkel Cell Carcinoma.

The American Journal of dermatopathology
2026

Cholecystectomy-Associated Postprandial Hypoglycemia.

AACE endocrinology and diabetes
2026

Three Interesting Cases of Hypoglycemia: A Case Series.

Cureus
2026

Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice.

EBioMedicine
2026

Systematic review of multimodal management strategies for Insulinoma-Induced hypoglycaemia: current evidence and future directions.

Endocrine
2026

Pediatric craniopharyngioma: when hypoglycemia reveals a brain tumor. Illustrative case.

Journal of neurosurgery. Case lessons
2026

Clinical Outcomes and Predictive Factors in Adrenalectomy: A Retrospective Cohort Study.

Iranian journal of pathology
2026

Noninsulinoma Hyperinsulinemic Hypoglycemia Syndrome Emerging Post-Nissen Fundoplication.

JCEM case reports
2026

Unveiling a Novel MT-TS1 m.7479G>A in Mitochondrial Diabetes: The Critical Role of mtDNA Sequencing in Atypical Cases.

JCEM case reports
2026

Investigating the Role of Diet-Manipulated Gut Bacteria in Pathogenesis of Type 2 Diabetes Mellitus-An In Vitro Approach.

Nutrients
2026

Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma.

BMJ case reports
2026

Unmasking an insulinoma: recurrent Hypoglycemia in a young patient following GLP-1 receptor agonist therapy -A case report.

Oxford medical case reports
2026

Insulinoma in a Young Patient With Focal Seizures: A Case Report of a Neurological Diagnostic Challenge.

Clinical case reports
2026

Association between spontaneous neurogenic atrophy of the femoral muscle and islet cell tumors in aged F344 rats.

Journal of toxicologic pathology
2026

A canine insulinoma with amphicrine differentiation: morphological and immunohistochemical characteristics.

Journal of toxicologic pathology
2026

A case report of enduring benefit of sequential PRRT in malignant insulinoma.

EJNMMI reports
2025

Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report.

Frontiers in endocrinology
2025

Germline and somatic mutations in histologically atypical congenital hyperinsulinism.

Frontiers in endocrinology
2026

Functionally coupled ion channels begin co-assembling at the start of their synthesis.

eLife
2026

Non-HLA risk variants in a type 1 diabetes pediatric population: Clinical and autoimmune profiles.

Anales de pediatria
2026

Dietary zinc deficiency regulates the ROS/TLR4/NF-κB pathway to induce pancreatic inflammation and cell death in mice.

The Journal of nutritional biochemistry
2026

[A case of recurrent hypoglycemic coma episodes associated with primary biliary cholangitis and literature review].

Zhonghua nei ke za zhi
2025

Elevated blood levels of liver-expressed antimicrobial peptide 2 in patients with insulinoma and its expression in insulinomas.

Frontiers in endocrinology
2026

A systematic review of the application of indocyanine green in pancreatic neuroendocrine tumors: Technical details, surgical indications, and outcomes.

HPB : the official journal of the International Hepato Pancreato Biliary Association
2025

Tumor enhancement by magnetic resonance imaging after endoscopic ultrasound-guided radiofrequency ablation for small pancreatic neuroendocrine tumors.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy
2026

Biogenic ZnO Nanoparticles from Allium Cepa and Tagetes erecta: Synthesis, Characterization and its Antidiabetic, Antioxidant Evaluation and Cytotoxic Studies against Mouse Insulinoma (MIN6) Cell Line.

Applied biochemistry and biotechnology
2025

Insulinoma in pregnancy: is diet alone enough to treat insulinoma?

Endokrynologia Polska
2026

Accuracy and reliability of a continuous glucose monitoring system with a focus on hypoglycaemia.

Diabetes, obesity &amp; metabolism
2025

Sinonasal Lymphoepithelial Carcinoma With Insulinoma-Associated Protein 1 (INSM1) Expression: A Potential Pitfall.

International journal of surgical pathology
2025

EUS-guided radiofrequency and ethanol ablation of pancreatic insulinomas: a single-center experience.

Therapeutic advances in gastrointestinal endoscopy
2025

DOCK10 Regulates Insulin Hypersecretion in Insulinoma and Serves as a Diagnostic and Therapeutic Target.

Cellular and molecular gastroenterology and hepatology
2025

Minimally Invasive Resection of Occult Insulinomas-Experience from an ENETS Centre of Excellence and Review of the Literature.

Cancers
2026

GADA as a biomarker for type 1 diabetes.

Clinica chimica acta; international journal of clinical chemistry
2025

Hyperbaric oxygen therapy for hypoglycaemic encephalopathy due to insulinoma: a case report.

Diving and hyperbaric medicine
2025

Gallbladder large cell neuroendocrine carcinoma in a patient with multiple myeloma: a case report and literature review.

Frontiers in oncology
2026

Insulinoma Unmasked By Tirzepatide: A Rare Case of Postprandial Hypoglycemia In a Nondiabetic Patient.

JCEM case reports
2025

A Rare Case of Presumed Insulin-Like Growth Factor 2 (IGF-2)-Mediated Hypoglycemia.

Cureus
2025

A case-based review of urachal carcinoma with mixed small cell neuroendocrine and adenocarcinoma components, with one new case report and analysis of nine published cases.

Frontiers in endocrinology
2025

Mono-(2-ethylhexyl) phthalate impairs insulin secretion in rat insulinoma cells by inducing ferroptosis via oxidative stress.

Ecotoxicology and environmental safety
2025

A Small-Molecule Mitofusin 1 Agonist Enhances Islet Survival Under Hypoxic Conditions In Vitro and Improves Transplantation Outcomes.

Biomolecules
2025

Quantitative Conspicuity of Pancreatic Canine Insulinoma: A Comparison of Dynamic 4D CT and Dual-Source, Dual-Energy Bolus-Triggered Multiphase CT Imaging.

Veterinary sciences
2025

Glucose shields RINm5F beta cells against arsenic-induced apoptosis.

Scientific reports
2025

Rare Causes of Hypoglycemia-Lessons from Case Reports.

JCEM case reports
2025

Dielectrophoresis Reveals Stimulus-Induced Remodeling of Insulin Granule Subpopulations.

bioRxiv : the preprint server for biology
2025

Successful Endoscopic Ultrasound-Guided Radiofrequency Ablation for Symptomatic Insulinoma in a High-Risk Elderly Patient.

ACG case reports journal
2025

Types of pancreatic lesions and the mutational landscape of the VHL gene in patients with von Hippel-Lindau disease.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
2025

68 Ga-NODAGA-EXENDIN-4 PET/CT in the Detection or the Exclusion of Occult Sporadic Insulinomas.

Clinical nuclear medicine
2026

Clinical Anatomy, Physiology, and Common Diseases of the Pancreas in Exotic Pets.

The veterinary clinics of North America. Exotic animal practice
2025

Developing 68Ga-Labeled Exendin(9-39) Derivatives for PET Imaging of Insulinomas.

Bioconjugate chemistry
2025

Enucleation for pancreatic neuroendocrine tumors: short- and long-term outcomes in a forty-year single-center experience.

Endocrine oncology (Bristol, England)
2025

A Case of Pediatric Pancreatic Insulinoma Diagnosed 4 Years after the Onset.

Surgical case reports
2025

Gastroenteropancreatic neuroendocrine neoplasms: Clinical-pathologic analysis of 48 cases treated at the Hospital Ángeles del Pedregal in Mexico City between 2018 and 2024.

Revista de gastroenterologia de Mexico (English)
2025

Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy.

JCEM case reports
2025

Immunohistochemical expression of Ki-67, INSM1, and SSTR2A in medullary thyroid carcinoma: correlation with tumour size, vascular invasion, and biochemical outcome.

Virchows Archiv : an international journal of pathology
2025

Microfluidic device for islet conformal coating with a polyethylene glycol-based hydrogel: innovating cell immunoprotection strategies in type 1 diabetes.

Lab on a chip
2025

Diagnostic and prognostic utility of insulinoma-associated protein 1, insulin gene enhancer protein 1, and secretagogin in pheochromocytoma.

Revista da Associacao Medica Brasileira (1992)
2025

The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinoma.

Investigational new drugs
2026

EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas-A Single-Center Experience.

The Journal of clinical endocrinology and metabolism
2025

A case of type 1 diabetes mellitus with a single-positive zinc transporter 8 antibody who developed diabetic ketoacidosis during chemotherapy for colorectal cancer.

Diabetology international
2025

An Unexpected Manifestation of Non-islet Cell Tumor Hypoglycemia in Pancreatic Ductal Adenocarcinoma.

Cureus
2025

Novel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms.

Diagnostic pathology
2025

Quality of Life After Pancreatic Surgery for Neuroendocrine Tumors of the Pancreas: Observational Study of Long-Term Outcomes.

Cancers
2025

OTUB1 Modulates Ferroptosis by Regulating SLC7A11 Ubiquitination in Pancreatic β-Cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Multiple endocrinopathies presenting simultaneously with insulinoma as the leading manifestation.

The American journal of medicine
2025

Endoscopic ultrasound-guided radiofrequency ablation for a pancreatic insulinoma: a novel endoscopic management strategy.

Endoscopy
2025

A 14-yr-old boy with a pathogenic MEN1 variant was diagnosed with asymptomatic insulinoma during routine follow-up.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2025

Identification of Peripheral Blood Endotypes Associated With Age in Pediatric Type 1 Diabetes.

Pediatric diabetes
2025

A Japanese infant with fulminant type 1 diabetes with disease-sensitive CSAD polymorphism and HLA haplotype.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
2025

Insulinoma initially misdiagnosed as migraine.

Archive of clinical cases
2025

Diagnostic Performance of Exendin-4 PET/CT in Localizing Insulinomas: A Systematic Review and Meta-analysis.

Academic radiology
2025

Percutaneous radiofrequency ablation of pancreatic insulinoma: A case report and literature review.

Radiology case reports
2026

Case report: Continuous glucose monitoring in insulinoma diagnosis and management.

The American journal of medicine
2025

Diazoxide as a bridging therapy in methadone-induced hypoglycemia- a case report and review of the literature.

Cardiovascular diabetology. Endocrinology reports
2025

Surgical Strategies for Tumors of the Pancreas and Duodenum.

Cancers
2025

Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.

Nuklearmedizin. Nuclear medicine
2025

I-BET151 modulates glucokinase gene expression and beta cell function in part through changes in FOXO1 expression.

Diabetologia
2025

Predictors of Transitions From GADA as the Initial Autoantibody to Multiple Autoantibodies of Type 1 Diabetes in Children at Risk by a Dynamic Prediction Model.

Pediatric diabetes
2025

Diagnosis and Surgical Management of Pancreatic Insulinoma in a Non-Diabetic Patient: A Case Report.

Reports (MDPI)
2025

Does X mark the spot? A case series of discrepant preoperative insulinoma localization.

Endocrinology, diabetes &amp; metabolism case reports
2025

Postoperative complications following surgery for congenital hyperinsulinism and insulinomas in pediatric patients.

Pediatric surgery international
2025

Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.

Diagnostics (Basel, Switzerland)
2025

Illuminating the Uncinate: Advanced Indocyanine Green Fluorescence and Ultrasound-Guided Robotic Enucleation of a Pancreatic Insulinoma in a Challenging Position.

Annals of surgical oncology
2025

Human Polyomavirus BK Genome Analysis in BKPyV Induced Rodent Cell Lines.

MicrobiologyOpen
2026

Analysis of islet antigen-specific autoreactive T cells from Japanese patients with slowly progressive insulin-dependent diabetes mellitus.

Immunology letters
2025

Mi-Lnc70 Regulates the Progression of Murine Pancreatic β-Cell Line and Affects the Synthesis of Insulin and Glucagon.

OncoTargets and therapy
2025

Enucleation for insulinoma: consolidating evidence through systematic review and meta-analysis.

Surgical endoscopy
2025

Allen Oldfather Whipple (1881-1963): A Pioneer of General Surgery.

Cureus
2025

Anatomical Preservation of Pancreatic Ducts in Partial Pancreatectomy: A Case Report of Canine Insulinoma.

Journal of the American Animal Hospital Association
2025

Anti-tumor potential of combinatory GSK3 inhibition in human 3D models of pancreatic neuroendocrine tumors and patient-derived GEP-NET primary cultures.

Endocrine-related cancer
2025

Diabetes, Celiac, and Thyroid-Related Autoantibodies in HLA Genotyped Ethiopian Children and Adolescents With Type 1 Diabetes: A Cross-Sectional Study.

Pediatric diabetes
2026

Insulinoma diagnosis and characterization with intratumoral heterogeneity employing [18F]FB(ePEG12)12-exendin-4 PET/MRI.

European journal of nuclear medicine and molecular imaging
2025

Dual Effect of 4-Methylumbelliferone on INS1E Cells: Enhancing Migration and Glucose-Stimulated Insulin Secretion.

International journal of molecular sciences
2025

Diagnostic Accuracy of Insulinoma-Associated Protein 1 in Pulmonary Neuroendocrine Carcinomas: A Systematic Review and Meta-Analysis.

Cancers
2025

The current status of serum insulin measurements and the need for standardization.

Clinical chemistry and laboratory medicine
2025

RNA binding protein HuD regulates fatty acid oxidation in pancreatic β-cells by modulating long-chain acyl-CoA dehydrogenase expression.

Animal cells and systems
2025

Rare pediatric insulinoma case diagnosed by endoscopic ultrasonography: insights into endogenous hyperinsulinemic hypoglycemia.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Anesthetic Management of a Patient With Suspected Insulinoma Undergoing Cardiopulmonary Bypass for Left Atrial Myxoma: A Case Report.

A&amp;A practice
2025

Recurrent Hypoglycemia in a Non-diabetic: A Case of Suspected Insulinoma Lost to Follow-Up.

Cureus
2025

Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.

European journal of endocrinology
2025

UNVEILING LADA: PREVALENCE AND CHARACTERISTICS AMONG TYPE 2 DIABETIC PATIENTS IN PORT SUDAN, SUDAN.

Georgian medical news
2025

Unlocking the Bioactivity of Sweet Wormwood (Artemisia annua L., Asteraceae) Ethanolic Extract: Phenolics, Antioxidants, and Cytotoxic Effects.

Pharmaceutics
2025

The thiazolidinedione drug troglitazone inhibits Gq signaling through direct binding to the Gq alpha subunit through inhibition of GDP release.

Molecular pharmacology
2025

Optimising insulinoma detection: Algorithm development and validation in a hospital discharge abstract database in China.

Health information management : journal of the Health Information Management Association of Australia
2025

Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours.

Endocrine oncology (Bristol, England)
2025

Chenodeoxycholic acid activates the TGR5/TRPA1-5-HT pathway to regulate intestinal motility in breastfed infants and mouse models.

Translational pediatrics
2025

Dexmedetomidine constant-rate infusion with additional partial intravenous anesthesia for a dog undergoing partial pancreatectomy for an insulinoma.

The Canadian veterinary journal = La revue veterinaire canadienne
2025

Novel germline likely pathogenic frameshift variant of the MEN1 gene contributes to multiple endocrine neoplasia type 1: a case report with review of literature.

Endocrine journal
2025

A new link between insulinoma and congenital glucose-galactose malabsorption.

Endocrine oncology (Bristol, England)
2025

Rapid Onset of Fulminant Type 1 Diabetes 10 Days After the First Dose of Nivolumab: A Case Report.

Cureus
2025

Clinically Adult-Onset Nesidioblastosis with Repeated Severe Hypoglycemia, Successfully Treated by Two Times Pancreatectomies. A Rare Case Report.

Clinical and experimental gastroenterology
2025

Nutritional Management of Functioning GEP-NENs.

Nutrients
2025

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and endoscopic ultrasound-guided ethanol ablation (EUS-EA) of pancreatic neuroendocrine tumors and adenocarcinoma: a prospective multicenter study.

Przeglad gastroenterologiczny
2025

Progenitor neighborhoods function as transient niches to sustain olfactory neurogenesis.

Stem cell reports
2025

Perioperative use and accuracy of continuous glucose monitoring: A systematic review.

Diabetes, obesity &amp; metabolism
2025

Evaluation of Metastatic Insulinoma With Severe Hypoglycemia Using 68 Ga-Exendin-4 PET/CT.

Clinical nuclear medicine
2025

68 Ga-DOTATATE PET/CT-Guided Surgical Resection for Complete Remission of Multifocal Insulinomas in a Father and Son With MEN1 Syndrome.

Clinical nuclear medicine
2025

Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up.

Endocrine pathology
2026

Ectopic Insulinoma in the Pyloric Antrum Portion of the Stomach: A Case Report and Review of the Associated Diagnostic Challenges.

Internal medicine (Tokyo, Japan)
2025

Pancreatic neuroendocrine tumors: A case-based evidence review.

World journal of gastrointestinal pathophysiology
2025

History of an Insidious Case of Metastatic Insulinoma.

Journal of clinical medicine
2025

Rapid Development of Breast Mass With Recurrent Episodes of Hypoglycemia Should Raise Suspicion of Breast Cancer With Insulinoma: A Case Report.

Cancer reports (Hoboken, N.J.)
2025

Pancreato-hepatobiliary neuroendocrine tumors diagnosed through endoscopic ultrasound: Clinical characteristics and factors associated with high-grade lesions.

World journal of gastrointestinal endoscopy
2025

Revealing the role of increased SK3 expression in sulfonylurea resistance triggered by prolonged exposure.

Nutrition &amp; diabetes
2025

Muscle-derived Stem Cell Exosomes Enhance Autophagy through the Regulation of the mTOR Signaling Pathway to Attenuate Glucolipotoxicity-induced Pancreatic β-cell Injury.

Current stem cell research &amp; therapy
2025

68 Ga-Exendin-4 PET/CT Enables Identification of Multiple and Ectopic Insulinoma in a Patient With Multiple Endocrine Neoplasia 1.

Clinical nuclear medicine
2025

Modulation of hIAPP Fibrillation by Rationally Designed Hexapeptides Revealed by Molecular Dynamics and Experimental Investigations.

ACS chemical neuroscience
2025

A hypoglycaemic 'Peter Pan': a paediatric disease in an adult patient?

Endocrinology, diabetes &amp; metabolism case reports
2025

Autoimmune hypoglycemia due to alpha-lipoic acid: Report of two cases.

Journal of postgraduate medicine
2025

Atypical Presentation of Insulinoma in a Patient With Hypoglycemia Unawareness: A Case Report.

Cureus
2025

Protective role of harmol against β-cell toxicity and glucose dysregulation in type 2 diabetes mellitus.

European journal of pharmacology
2025

Moving Beyond Glycated Hemoglobin to Glucose Patterns: Newer Indications for Continuous Glucose Monitor Use.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Successful treatment of metachronous insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome.

Polish archives of internal medicine
2025

Improved detection and localization of insulinoma using small field-of-view diffusion-weighted MRI: A case report.

Radiology case reports
2025

Bifocal Insulinoma Detected With 68 Ga-Exendin PET/CT and Treated With Endoscopic Ultrasound-guided Radiofrequency Ablation: Toward a Gold-Standard Management?

Clinical nuclear medicine
2025

Six-Year Outcomes Following Stereotactic Body Radiation Therapy for Insulinoma: A Case Report and Literature Review.

Cureus
2025

Polymerized laminin-modified microcapsules improve pancreatic islet resilience towards cytokine induced inflammatory stress and lower chemoattractant cytokine secretion.

Materials today. Bio
2025

Prevalence of Diabetes-related Autoantibodies Among Individuals With Type 2 Diabetes From Primary Care and Endocrinology Community Practice Settings.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

Comparative efficacy of systemic therapies in malignant insulinoma.

Endocrine-related cancer
2025

Comparative cytotoxicity and toxicological mechanisms of 6:2 Cl-PFAES and PFOS in pancreatic β cells: implications for glucose metabolism disruption.

Environmental science. Processes &amp; impacts
2025

Single-cell transcriptomic analysis of canine insulinoma reveals distinct sub-populations of insulin-expressing cancer cells.

Veterinary oncology (London, England)
2025

Single-cell transcriptome conservation in a multispecies comparative analysis of fresh and cryopreserved insulinoma cell lines.

Veterinary oncology (London, England)
2025

In-Hospital Postoperative Glycemic Trends After Pancreatic Insulinoma Resection.

The Journal of surgical research
2025

Peptide receptor radionuclide therapy in malignant insulinoma.

Endocrine-related cancer
2025

Recurrence of malignant insulinoma in the context of multiple endocrine neoplasia type 1: a case report.

Journal of surgical case reports
2025

Case Report: A case of occult insulinoma localized by [18F] FB (ePEG12)12-exendin-4 positron emission tomography with negative findings of selective arterial calcium stimulation test.

Frontiers in endocrinology
2025

Uhrf1 downregulation promotes β-cell dedifferentiation by decreasing Foxo1 expression in type 2 diabetes.

Journal of diabetes investigation
2025

Medically Refractory Nesidioblastosis as a Late Adverse Effect of Roux-en-Y Gastric Bypass.

Cureus
2025

Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.

The Journal of clinical endocrinology and metabolism
2025

TEAD switches interacting partners along neural progenitor lineage progression to execute distinct functions.

Genes &amp; development
2026

Localization of Benign Insulinomas With a Radionuclide Tracer Targeting the GLP-1 Receptor With Pegylated Exendin-4.

The Journal of clinical endocrinology and metabolism
2025

Pancreatic neuroendocrine tumors - going beyond surgery. Literature review and experience of a tertiary center.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
2025

Case Report: Diazoxide-induced diabetic ketoacidosis in a patient with insulinoma.

Frontiers in endocrinology
2025

Pancreatic neuroendocrine tumors: Do we need more nuanced staging?

American journal of surgery
2025

Expression of insulinoma-associated protein 1 (INSM1) in gastric neuroendocrine and non-neuroendocrine neoplasms.

Discover oncology
2025

Association of type 1 stiff-person syndrome and insulinoma: a case report and narrative review.

Hormones (Athens, Greece)
2025

Aldolase-regulated G3BP1/2+ condensates control insulin mRNA storage in beta cells.

The EMBO journal
2025

Gastrointestinal Amphicrine Carcinoma: A Clinicopathologic Study of Five Patients.

International journal of surgical pathology
2025

Nesidioblastosis post-bariatric surgery in an adult patient: a case report and review of literature.

Annals of medicine and surgery (2012)
2025

Undiagnosed Insulinoma in a Young Patient With Idiopathic Dilated Cardiomyopathy: A Case Report.

Cureus
2025

Insulin autoimmune syndrome in a patient with vitiligo: a case report and review of literature.

Journal of medical case reports
2025

Glucagon-like peptide-1 receptor PET/CT with 68Ga-exendin-4 for localizing insulinoma: a real-world, single-center study.

European journal of nuclear medicine and molecular imaging
2025

Mechanosensitive Channels Mediate Pancreatic β Cells Reactive Oxygen Species Formation and Downregulation of Essential Genes During Therapeutic Ultrasound Treatment.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
2025

Slowly Progressive Type 1 Diabetes following Steroid-Sensitive Relapsing Nephrotic Syndrome in Childhood: A Case Report.

Biomedicine hub
2025

Impact of the Addition of Beta-Hydroxybutyrate in the 72-Hour Fast Protocol on Hospitalization Duration: A Quality Improvement Report.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025

GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades.

Virchows Archiv : an international journal of pathology
2025

Multicenter Study on the Clinical Characteristics, Diagnosis, and Treatment Outcomes of Insulinoma: Insights From 15 Medical Centres.

Clinical endocrinology
2025

Temporal Effects of a Viral Peptide on Glucose-Stimulated Insulin Secretion.

ACS infectious diseases
2025

Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.

European journal of nuclear medicine and molecular imaging
2026

Insulin Autoimmune Syndrome: Imaging Findings and Uptake Pattern With 68 Ga-Exendin-4 and 68 Ga-DOTATATE PET-CT.

Clinical nuclear medicine
2025

Diagnostic and Surgical Management of Nesidioblastosis in a 42-Year-Old Man with Refractory Hypoglycemia.

The American journal of case reports
2025

Evaluation of Serum Level of Chemokine (C-C Motif) Ligand 2 (CCL2) in Canine Urothelial Carcinomas, Mast Cell Tumours, and Insulinomas, and Its Correlation With Circulating Monocytes.

Veterinary and comparative oncology
2025

Identification of a Selective Pharmacologic IRE1/XBP1s Activator with Enhanced Tissue Exposure.

ACS chemical biology
2025

Insulinoma: A Novel Presentation of Multiple Endocrine Neoplasia 4.

AACE clinical case reports
Ver todos os 2.971 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Insulinoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Insulinoma

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Development and characterization of experimental &#x3b2;-cell senescence models revealing autophagy defects and altered stimulus-secretion coupling.
    GeroScience· 2026· PMID 41803428mais citado
  2. Evaluation of Clinical, Laboratory and Immunological Characteristics in the Early Onset (Diagnosed Age &lt; 30 Years Old) Patients With Type 2 Diabetes.
    Journal of Korean medical science· 2026· PMID 41732045mais citado
  3. Targeted near-infrared imaging utilizing a cathepsin-activated fluorophore for the intraoperative detection of canine insulinoma.
    PloS one· 2026· PMID 41729951mais citado
  4. Type 1 Diabetes: A Review.
    JAMA· 2026· PMID 41697686mais citado
  5. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic insulinoma.
    BMJ case reports· 2026· PMID 41592882mais citado
  6. A Case of Functional Para-Aortic Paraganglioma Causing Accelerated Hypertension in an HIV-Positive Patient With Negative 68Ga-DOTATATE PET/CT Findings: Successful Laparoscopic Management.
    Cureus· 2026· PMID 41994760recente
  7. Real-world treatment outcomes for pancreatic neuroendocrine tumours: a single tertiary referral institute experience.
    ESMO Gastrointest Oncol· 2026· PMID 41994027recente
  8. Insulinoma-associated 1 promotes neurogenic proliferation of cortical basal progenitors but is largely dispensable for projection neuron production.
    bioRxiv· 2026· PMID 41993508recente
  9. Whole-exome sequencing unveils novel potential gene mutations involved in primary renal small cell carcinoma.
    Oncol Lett· 2026· PMID 41969585recente
  10. Adjuvant nutritional management of canine insulinoma: A case report.
    Res Vet Sci· 2026· PMID 41967456recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:97279(Orphanet)
  2. MONDO:0005048(MONDO)
  3. GARD:3010(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q1501239(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Insulinoma
Compêndio · Raras BR

Insulinoma

ORPHA:97279 · MONDO:0005048
Prevalência
1-9 / 1 000 000
Herança
Not applicable
CID-10
D37.7 · Neoplasia de comportamento incerto ou desconhecido de outros órgãos digestivos
CID-11
Ensaios
7 ativos
Início
All ages
Prevalência
0.56 (Japan)
MedGen
UMLS
C0021670
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades